单灶性与多灶性首次复发上皮性卵巢癌继发性细胞减少手术后化疗的附加价值：一项系统综述

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2025-07-18 DOI:10.1016/j.gore.2025.101809

R.E.W.M. van de Vorst , M.D. Huiskamp , E.H. Gort , P.O. Witteveen , R.P. Zweemer , C.G. Gerestein

{"title":"单灶性与多灶性首次复发上皮性卵巢癌继发性细胞减少手术后化疗的附加价值：一项系统综述","authors":"R.E.W.M. van de Vorst , M.D. Huiskamp , E.H. Gort , P.O. Witteveen , R.P. Zweemer , C.G. Gerestein","doi":"10.1016/j.gore.2025.101809","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This systematic review aims to evaluate the added value of chemotherapy after secondary cytoreductive surgery (SCS) on survival in patients with unifocal and multifocal first recurrent epithelial ovarian cancer (EOC). Moreover, it compares survival outcomes between unifocal and multifocal recurrences in treatment outcomes.</div></div><div><h3>Methods</h3><div>A systematic search was conducted across PubMed, Embase, and the Cochrane Library identified 907 articles. Studies were selected if they involved patients with first recurrent EOC undergoing SCS, stratified by unifocal or multifocal recurrence. The primary outcomes were progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>No studies specifically addressed the added value of chemotherapy after SCS in unifocal versus multifocal first recurrent EOC. This systematic review identified eight studies examining PFS and OS in patients with unifocal and multifocal first recurrent EOC following SCS with chemotherapy. Findings consistently show that unifocal first recurrent EOC is associated with significantly improved PFS and OS compared to multifocal first recurrent EOC. However, the extent of the survival benefit varied. Six studies showed an advantage for unifocal recurrence on multivariate analyses, although two studies did not find statistically significant differences after adjusting for other variables.</div></div><div><h3>Conclusion</h3><div>This review shows that there is a knowledge gap regarding the added value of chemotherapy after complete SCS in first recurrent EOC. However, this review shows a survival advantage of unifocal over multifocal first recurrent EOC. There is a need for clinical trials to compare survival outcomes between unifocal and multifocal first recurrent EOC patients undergoing SCS alone or SCS with chemotherapy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101809"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The added value of chemotherapy after secondary cytoreductive surgery in unifocal versus multifocal first recurrent epithelial ovarian cancer: A systematic review\",\"authors\":\"R.E.W.M. van de Vorst , M.D. Huiskamp , E.H. Gort , P.O. Witteveen , R.P. Zweemer , C.G. Gerestein\",\"doi\":\"10.1016/j.gore.2025.101809\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>This systematic review aims to evaluate the added value of chemotherapy after secondary cytoreductive surgery (SCS) on survival in patients with unifocal and multifocal first recurrent epithelial ovarian cancer (EOC). Moreover, it compares survival outcomes between unifocal and multifocal recurrences in treatment outcomes.</div></div><div><h3>Methods</h3><div>A systematic search was conducted across PubMed, Embase, and the Cochrane Library identified 907 articles. Studies were selected if they involved patients with first recurrent EOC undergoing SCS, stratified by unifocal or multifocal recurrence. The primary outcomes were progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>No studies specifically addressed the added value of chemotherapy after SCS in unifocal versus multifocal first recurrent EOC. This systematic review identified eight studies examining PFS and OS in patients with unifocal and multifocal first recurrent EOC following SCS with chemotherapy. Findings consistently show that unifocal first recurrent EOC is associated with significantly improved PFS and OS compared to multifocal first recurrent EOC. However, the extent of the survival benefit varied. Six studies showed an advantage for unifocal recurrence on multivariate analyses, although two studies did not find statistically significant differences after adjusting for other variables.</div></div><div><h3>Conclusion</h3><div>This review shows that there is a knowledge gap regarding the added value of chemotherapy after complete SCS in first recurrent EOC. However, this review shows a survival advantage of unifocal over multifocal first recurrent EOC. There is a need for clinical trials to compare survival outcomes between unifocal and multifocal first recurrent EOC patients undergoing SCS alone or SCS with chemotherapy.</div></div>\",\"PeriodicalId\":12873,\"journal\":{\"name\":\"Gynecologic Oncology Reports\",\"volume\":\"60 \",\"pages\":\"Article 101809\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologic Oncology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352578925001341\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925001341","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的本系统综述旨在评价单灶性和多灶性首次复发上皮性卵巢癌（EOC）患者继发性细胞减少手术（SCS）后化疗对生存的增加价值。此外，它比较了单灶性和多灶性复发在治疗结果中的生存结果。方法系统检索PubMed、Embase和Cochrane图书馆的907篇文献。如果研究涉及首次复发的EOC接受SCS的患者，根据单灶或多灶复发进行分层。主要结局为无进展生存期（PFS）和总生存期（OS）。结果没有研究专门讨论单发灶与多发灶首次复发EOC SCS后化疗的附加价值。本系统综述确定了8项研究，研究SCS化疗后单灶性和多灶性首次复发EOC患者的PFS和OS。研究结果一致表明，与多灶性首次复发EOC相比，单灶性首次复发EOC与显著改善的PFS和OS相关。然而，生存获益的程度各不相同。在多变量分析中，有6项研究显示了单病灶复发的优势，尽管有2项研究在调整其他变量后没有发现统计学上的显著差异。结论对首次复发EOC的完全SCS后化疗的附加价值存在认识空白。然而，这篇综述显示单灶性EOC比多灶性EOC有生存优势。有必要进行临床试验来比较单灶性和多灶性首次复发EOC患者单独接受SCS或SCS联合化疗的生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The added value of chemotherapy after secondary cytoreductive surgery in unifocal versus multifocal first recurrent epithelial ovarian cancer: A systematic review

Objective

This systematic review aims to evaluate the added value of chemotherapy after secondary cytoreductive surgery (SCS) on survival in patients with unifocal and multifocal first recurrent epithelial ovarian cancer (EOC). Moreover, it compares survival outcomes between unifocal and multifocal recurrences in treatment outcomes.

Methods

A systematic search was conducted across PubMed, Embase, and the Cochrane Library identified 907 articles. Studies were selected if they involved patients with first recurrent EOC undergoing SCS, stratified by unifocal or multifocal recurrence. The primary outcomes were progression-free survival (PFS) and overall survival (OS).

Results

No studies specifically addressed the added value of chemotherapy after SCS in unifocal versus multifocal first recurrent EOC. This systematic review identified eight studies examining PFS and OS in patients with unifocal and multifocal first recurrent EOC following SCS with chemotherapy. Findings consistently show that unifocal first recurrent EOC is associated with significantly improved PFS and OS compared to multifocal first recurrent EOC. However, the extent of the survival benefit varied. Six studies showed an advantage for unifocal recurrence on multivariate analyses, although two studies did not find statistically significant differences after adjusting for other variables.

Conclusion

This review shows that there is a knowledge gap regarding the added value of chemotherapy after complete SCS in first recurrent EOC. However, this review shows a survival advantage of unifocal over multifocal first recurrent EOC. There is a need for clinical trials to compare survival outcomes between unifocal and multifocal first recurrent EOC patients undergoing SCS alone or SCS with chemotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.